| 1886 |
Wyeth starts smallpox vaccine production, the first step in eradicating this devastating disease |
| 1906 |
Dr Ernest Lederle founds Lederle Laboratories and diphtheria vaccine is launched |
| 1942 |
Wyeth ships typhus vaccine as part of the war effort to protect armed forces against the disease most frequently seen during times of war and deprivation |
| 1947 |
Lederle introduces a combined vaccine for preventing diphtheria, tetanus and pertussis in young children |
| 1960 |
Wyeth produces a freeze-dried smallpox vaccine providing the high quality and added stability needed for mass vaccination |
| 1963 |
Lederle introduces the first oral form of the live trivalent poliovirus vaccine dramatically reducing the incidence of this crippling disease |
| 1968 |
Wyeth waives patent royalties on its innovative bifurcated (two pronged) needle aiding in the delivery of 200 million life saving smallpox vaccinations per year |
| 1990 |
Introduction of the first Haemophilus influenzae type b conjugated vaccines for infants helps reduce the occurrence of this major invasive bacterial disease |
| 1991 |
Introduction of the first diphtheria, tetanus and acellular vaccine for children under 7 |
| 1992 |
HibTITER™ Haemophilus influenzae type b conjugated vaccine is launched in the UK as part of a national immunisation campaign against a leading cause invasive bacterial disease |
| 1995 |
Merger of Wyeth with the American Cyanamid Company (formerly Lederle) |
| 1997 |
Wyeth launches 2 new vaccines in the UK. Pnu-Imune™ is a vaccine against pneumococcal disease caused by the most common types of Streptococcus pneumoniae. Begrivac™ is an inactivated influenza vaccine based on recommendations by the World Health Organization |
| 1999 |
Wyeth’s Meningitec®, Meningococcal group C conjugate to protect against meningitis and septicaemia introduced in the UK |
| 2000 |
Prix Galien award for the world’s first conjugate vaccine Meningitec, against meningococcal group C (meningitis C). It was prioritised to enable the NHS vaccination programme to begin and has led to a major reduction in cases of this life-threatening disease |
| 2001 |
European licence granted for Wyeth’s Prevenar - a 7 valent pneumococcal conjugate vaccine |
| 2004 |
Awarded a 2nd Prix Galien award for the world’s first conjugate vaccine against serious pneumococcal disease in children – such as meningitis, septicaemia and pneumonia. The vaccine is recommended for inclusion in the UK child immunisation programme |
| 2006 |
Pneumococcal conjugate vaccine introduced into UK routine childhood immunisation schedule |
| 2007 |
World Health Organization recommends that priority should be given to introducing the pneumococcal conjugate vaccine into childhood immunisation programmes worldwide |
| 2008 |
Wyeth submit a broader coverage, 13 valent pneumococcal conjugate vaccine for regulatory approval in Europe |
| 2009 |
The UK Department of Health estimates that 959 cases of pneumococcal disease and 53 deaths have been prevented since the introduction of Prevenar® into the UK childhood immunisation schedule |
| 2009 |
Pfizer acquires Wyeth |
| 2010 |
The Department of Health award Pfizer the national contract to supply Prevenar 13® for the UK childhood immunisation programme, ensuring children in the UK have the broadest available coverage against pneumococcal disease |